Patent protection is a critical driver of value for the biotech industry. One of the unique aspects of biotech patents, however, is that many otherwise infringing activities are exempt from claims of patent infringement when...more
In This Issue:
Federal Courts Debate Safe Harbor Exemption for Patent Infringement Under 35 U.S.C. ยง 271(e) Following Merck v. Integra; If I Prioritize Examination of My Application, Should the Patent Office?;...more
2/19/2013
/ Biotechnology ,
Discovery ,
Exemptions ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Infringement ,
Integra ,
InterDigital Communications v ITC ,
Merck ,
Non-Practicing Entities ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Prioritized Examination ,
Safe Harbors